Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VISION: Pluvicto in mCRPC
NCT03511664Phase 3Completed
- Sponsor
- Endocyte
- Start
- May 2018
- Primary completion
- Jan 2021
- Modality
- Small Molecules, Peptide-Drug Conjugates
- Countries
- 10
01
Overview
A Phase 3 trial of lutetium-177 PSMA in metastatic castration-resistant prostate cancer (mCRPC), sponsored by Endocyte. Started May 2018; status: completed.
02
Drugs
lutetium-177 PSMA
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT03511664.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03511664.